Are you enrolling patients in clinical trials?

Not yet. But if you or someone you love would be interested in a biomaterials-based approach as part of the road to recovery, please consider leaving a post on our Patient Connection page. Your stories and support keep us motivated to find new solutions, and they add urgency to push toward clinical trials. By sharing an experience, you not only remind others that they are not alone, but you also encourage the rest of the scientific community to join us in finding solutions for the treatment of stroke and non-healing wounds.

For up-to-date milestone announcements, please follow us on Twitter.

Does your material work in humans?

Our materials have not yet been tested in humans. The in vivo results presented on our Research page are gathered from murine (mouse) models. We are working to perfect the efficacy and safety of our materials before entering clinical trials. Follow us on Twitter where we post milestone announcements.

What is your approach to reduce physical disability after stroke?

We are developing biomaterials that are designed to be injected into the stroke cavity of the brain in order to promote neuronal growth where tissue has been lost. By encouraging tissue regrowth, we aim to restore function and reverse disability.

Physical disability after stroke is the result of brain tissue that was permanently damaged while the brain was deprived of oxygen. Current stroke treatments must be administered within hours after the attack and aim to minimize neuronal death (think damage control), which in turn minimizes the severity of disability. In contrast to this standard of care, our material will offer patients an additional therapeutic option that can be administered days to months after the stroke with the goal of catching the brain during the healing process and encouraging it to regenerate dead tissue instead of filling the space with a non-functional scar. In this way, our material attempts to recover brain function and reduce physical disability. Read more on our Research page.

What is your approach to promote skin wound healing?

We are engineering biomaterial gels that can be delivered directly into skin wound beds to behave as tissue mimics that speed up the healing process and improve the overall outcome of skin quality. In cases where patients have wounds that never fully heal, our materials are designed to calm inflammation in order to allow the body to progress to the later stages of wound healing. The secret to our madness is in the chemical composition and microarchitecture of our gels that are engineered to influence the cellular microenvironment of the wound. We go into more detail on our Research page.

What are your biomaterials made out of?

The majority of our materials are made from either hyaluronic acid (HA) or polyethylene glycol (PEG). HA a naturally-derived polymer found in abundance throughout our bodies (you may have noticed this ingredient in a lot of cosmetic products aimed at rejuvenating the skin). PEG, on the other hand, is a synthetically-derived polymer that has been studied for years and has been used in a wide range of medical products because of how safe it is (it gets the FDA stamp of approval ). After choosing a base material, we then perform a number of chemical modifications to get the polymers up to speed for our wound healing applications. But of course, we can never stop exploring, and our materials are not limited to HA and PEG.

Are you accepting new students or postdocs into your lab?

Yes, we are always looking for talented, self-driven, inspired students / postdocs to work with us. Please visit our Contact page for ways to reach out and / or apply.

Do you collaborate with other labs?

Yes, science and progress rely on collaborations! We don’t have a consolidated list of all of our collaborations; however, our Publications page may give a clue. If you are interested in learning how to make our materials or in using our materials for new applications, please reach out using our Contact page.

Is your technology patented?

Yes, we patent our technology whenever possible. We have 9 issued patents, 14 applications, and several more that have been disclosed. The most recent patents cover our MAP scaffold technology and our D-peptide technology, but you can find all of our patents on our Publications page.

What are your funding sources?

The Segura lab has been very fortunate to be funded through a variety of sources since its early years. More recently in 2020, Professor Segura received three NIH R01 grants totaling more than $6 million to use toward developing regenerative biomaterials for brain and skin.

While we’re on the subject, we’d like to take this opportunity to thank all of our sponsors. A special thanks goes to our biggest supporters: the National Science Foundation, the National Institutes of Health (NIH), and the American Heart Association.

What's up with this swanky website?

This website exists because Professor Segura was awesome enough to let Lindsay go wild with her vision for a fun and feminine lab website – who says science has to be sterile and unisex? The design was inspired by her favorite websites, and all of the content was generated in-house – meaning anyone can do it too! Cartoons and animated gifs were created in Procreate – cinemagraphs were created in Photoshop – videos were edited in iMovie – and for pictures, if it wasn’t taken on a microscope, it was pretty much taken with an iPhone.

To bring her vision to life, the Segura lab partnered with the incredible team at Citrus Studios in Los Angeles, CA. Reach out! They’re the friendliest group of web developers you’ll meet. And for Youtube videos where Tatiana Explains, we’re leaving the editing to our friend Nidal in Los Angeles.


We are deeply motivated and affected by the stories shared by real patients and families.

We welcome you to ask questions, share your thoughts, or introduce us to the individuals we are working to help.

    • Are you planning on doing clinical trials regarding the gel for brain replasticity? And if so, when? Also, where can one find articles about the research. Thank you. My daughter suffered from StrepB meningitis as a baby and suffered 2 strokes. She has had some replasticity and I’m grateful — we are Stemcell pioneers, which has been beneficial. And I’m always looking for newer and successful ways to further bring more cognitive and functional recovery into my daughter's life.

      Response from: Professor Tatiana Segura

      Lisa, thank you for sharing your daughter’s story. It’s incredible to hear about her neuroplasticity. We are not at the stage of clinical trials, so unfortunately, we don’t have an expected date. However, hearing about stroke in such a young patient who has shown signs of replasticity is immensely motivating to my lab and the scientific community. If you go onto the Publications page of our website and filter by ‘Topic > Stroke,’ you will be able to see our relevant publications. If you include ‘Type > Primary research’ in your filter, you will see our novel work in the field. Please don’t hesitate to reach out through our Contact Page if you have additional questions.
    • My wife recently had a pontine ischemic stroke because of a blood clot in the basilar artery. She now has "locked-in" syndrome because of the area of the stroke on the pons. Now that this has happened we are seeing the scans where she has TIA's in the past we didn't know about. This most devastating stroke occurred 2/4 and was at first misdiagnosed by the attending physician at our local hospital and now is paying the price for their lack of accepting the symptoms we described to them which we now know were stroke symptoms. I would give an arm and a leg to get back my beloved Debbie in any form but this. I encourage you to step up human trials and let us know when you do as we would participate. Thanks for your time and please help us stop the suffering she is going through.

      Response from: Professor Tatiana Segura

      Alan, you have shared an absolutely devastating story that has touched the hearts of everyone in our lab. I am shaken to hear of such an extreme outcome from stroke, and you have raised awareness for how serious the condition can be. We have not yet studied stroke in the basilar artery, but thank you for bringing this important site to our attention. Clinical trials are our goal, and your story serves as sincere motivation for pushing our technology in that direction.
    • When I was a teenager I quickly developed an infectious cyst on the skin near my eye. I had to have surgery quickly before my vision was lost. Thankfully the surgery was performed in time but it has left me with a very unsightly facial scar which dramatically effects my daily life. I have practically no self esteem, depression and anxiety. Mental health treatment has not helped in the 7 years past. I need a reduction in the scarring to flourish. My most humble gratitude to Professor Segura and everybody associated for working on this. I would love to be part of trials in the future.

      Response from: Professor Tatiana Segura

      Joey, thank you for sharing your story. It is so important for my team and me to learn about all of the different people we could help. So far, we have not worked on treating pre-existing scars but rather preventing scarring during initial healing. However, your story brings attention to this important problem, and I hope it inspires a solution.
    • On September 17, 2017 at the age of 49, I suffered a spontaneous right carotid artery dissection. At the time, I was an extremely active and healthy person. Unfortunately, as we didn’t realize what was happening to me, I didn’t make it to the hospital in time to get the clot-busting shot that most likely would have prevented the left-side paralysis I suffered from my massive stroke. We learned, only after the fact that time is of the utmost importance when you first experience stroke symptoms. In fact, we didn’t know the first thing about stroke protocols. Since being in the ICU for two weeks, followed by 6 weeks of inpatient and years of outpatient therapy I am now out of the wheelchair. However I still remain paralyzed on my left side with no functional arm use and limited left leg mobility. I have spent years researching clinical trials for Stroke with no luck. I was extremely excited to read about your hydrogel therapy and still hold out hope that I will one day be able to participate in a trial that may help this therapy become a treatment for stroke survivors.

      Response from: Professor Tatiana Segura

      Rachel, thank you for sharing your story. As you read, we are working on a biomaterial-based approaches to treat the disability caused by stroke. Although we have some promising results, we have only tested them in small animal models of stroke, so it would be some time before we can test them in a clinical trial. I am very moved that you found our research and found some hope in it.
    • In 2005 Derek had a Pilonidal Cyst removed, which was much more extensive than expected. After the surgery he had a wound vac to help heal the wound, which didn’t help and he still had a pretty large open wound. About a year later he had another surgery on the wound site to try to get it to close, but that was unable to help. At one point, we found a Doctor and Hospital in Arkansas that was doing PRP wound treatments. Derek went there where they debrided the wound, applied the PRP and sealed the wound for 1 week. When the bandage was removed the wound had healed, however several months later it opened again. Unfortunately the tissue wasn’t strong enough to stay in place; and since that time Derek’s wound has been open with seepage and occasional reinfections. In the years following, we had had numerous doctors tell us that there was nothing that they could do to heal the wound. In our home treatments, we have used Silvasorb and other topical ointments to help healing, but they do nothing other than reduce the seepage for a short period of time. This obviously affects his daily life as in his activities, how he sits down, to seepage through his clothes and some pain.

      We know you have been doing a lot of research on wound therapy, is this hydrogel looking promising in the near future for Derek’s type of wound? Or any other treatments available?

      Response from: Professor Tatiana Segura

      Steve, thank you for sharing Derek's story. It is very crazy to me that we still have such a hard time closing up skin wounds. But it is true, some wounds just do not heal well or at all. For skin, our technology is much closer to the clinic. We have licensed our MAP hydrogel to Tempo Therapeutics in San Diego, and they are getting ready for FDA approval. Please keep checking our website and their website for information on a possible in-patient trial. We are continuing to improve the material as well to improve the strength of the tissue that gets deposited.